Growing knowledge suggests, however, that EGFR-mediated tumourigenic mechanisms as well as EGFR-targeted therapeutic approaches are very different for this tumour type when compared with better understood NSCLC or colorectal cancers. The gene discussed is EGFR; the disease is colorectal cancer.